Raul Shah, CEO of DocShah Financial, analyzes the potential Wall Street implications of the FDA’s impending decision on peptide regulation, takes a closer look at how Hims & Hers could benefit from approval and shares his health care sector insights. Raul also explains why he still believes in UnitedHealth and why he’ll always be a value investor.